Anavex Life Sciences to Present at the Citizens Life Sciences Conference
Rhea-AI Summary
Anavex Life Sciences (Nasdaq: AVXL) will present at the Citizens Life Sciences Conference. Christopher U Missling, PhD, President & CEO, is scheduled to speak on Tuesday, March 10, 2026 at 11:55 AM ET.
The presentation covers company developments in clinical-stage CNS programs including Alzheimer’s, Parkinson’s, schizophrenia, Rett syndrome and other neurodegenerative and rare diseases.
Positive
- None.
Negative
- None.
News Market Reaction – AVXL
In the Mar 3 session, AVXL gained 3.53%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.7% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Conference appearance | Positive | +0.9% | Announcement of TD Cowen health care conference presentation and webcast access. |
| Feb 23 | Board appointment | Positive | +1.0% | Appointment of experienced healthcare leader to strengthen Board governance. |
| Feb 09 | Earnings and update | Positive | +6.1% | Q1 2026 results with cash position and updates on CNS clinical programs. |
| Feb 03 | Earnings date set | Neutral | -2.9% | Scheduling of Q1 2026 results release and investor call details. |
| Jan 13 | Clinical initiative | Positive | +8.2% | Participation in ACCESS-AD precision-medicine initiative for Alzheimer’s with blarcamesine. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent AVXL headlines, including conferences, governance updates, and clinical initiatives, have more often seen modestly positive price reactions, with only the earnings-date notice drawing a negative move.
Over recent months, AVXL has issued a mix of clinical, financial, and event-related updates. On Jan 13, 2026, joining the ACCESS-AD initiative tied to blarcamesine coincided with an 8.16% gain. The Feb 9, 2026 Q1 results and business update saw a 6.1% rise, reflecting interest around cash levels and CNS programs. Board strengthening on Feb 23, 2026 and multiple conference presentations have produced smaller positive moves. Today’s Citizens Life Sciences Conference appearance fits this pattern of frequent investor-relations and visibility events.
Key Terms
central nervous system (cns) medical
rett syndrome medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the Citizens Life Sciences Conference on Tuesday, March 10th, 2026 at 11:55 AM (ET).
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
